- Home
- ASRT vs TLSA Comparison
ASRT vs TLSA Comparison
Compare ASRT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | TLSA |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 155.2M |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ASRT | TLSA |
|---|---|---|
| Price | $18.60 | $1.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 146.7K | 146.6K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,713,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.73 |
| 52 Week High | $20.45 | $2.60 |
Technical Indicators
Market Signals| Indicator | ASRT | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 46.97 |
| Support Level | $0.70 | $1.24 |
| Resistance Level | $20.45 | $1.62 |
| Average True Range (ATR) | 1.37 | 0.11 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 76.21 | 36.84 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.